TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02160704
Drug: Enclomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Enclomiphene (DB06735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg daily for 16 weeks
Study: NCT01843062
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 capsules of 25 mg strength orally twice a day for approximately 5 weeks treatment period
Study: NCT01843062
Drug: Radioactive Iodine Therapy
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization. Additionaly, Thyrogen (Recombinant human TSH) will be used to stimulate iodine uptake according to the manufacturer's recommendation(0.9 mg intramuscular injection once a day for the 2 days prior to the dose of radioactive iodine)
Study: NCT01185925
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil, 50 mg 3 times/day
Study: NCT00073112
Drug: ABT-751
Normalized name: ABT-751
DrugBank: ABT-751 (DB12254)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00696930
Drug: 90Y-SMT487
Normalized name: 90Y-HPAM4
DrugBank: T487 (DB05474)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00292799
Drug: Orlistat Vs Metformin
Normalized name: Orlistat
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02652650
Drug: Ethinylestradiol
Normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 35 microgram (mcg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
Study: NCT02652650
Drug: Norethindrone
Normalized name: Norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 1 milligram (mg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
Study: NCT02652650
Drug: JNJ-63623872
Normalized name: JNJ-63623872
DrugBank: Pimodivir (DB14974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 600 mg twice daily (bid) for 5 days on Days 73 to 77 (Cycle III: OC plus JNJ-63623872, test) during third OC cycle under fed conditions.
Study: NCT04906304
Drug: Everolimus Pill
Normalized name: everolimus Pill
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: standard dose versus low dose Sandimun
Study: NCT04906304
Drug: Sandimmun (Neoral) dose plus cellcept
Normalized name: Cellcept
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sandimmun (Neoral) dose plus cellcept
Study: NCT00994422
Drug: Ivermectin cream
Normalized name: Ivermectin Cream
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1.
Study: NCT00994422
Drug: vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
Study: NCT00756990
Drug: Depot Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 228mg of injectable naltrexone
Study: NCT02992392
Drug: Liposic
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one eye of the participant recieved Lipoic
Study: NCT02992392
Drug: Tears Naturale Forte
Normalized name: Tears Naturale Forte
DrugBank: Dextran (DB09255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the other eye of the participant recieved Tears Naturale Forte
Study: NCT01294683
Drug: Extended Release (ER) niacin/laropiprant (N/LRPT)
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03212430
Drug: L-kynurenine
Normalized name: L-377202
DrugBank: Kynurenine (DB02070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of L-kynurenine to healthy individuals.
Study: NCT01806675
Drug: 18F-fludeoxyglucose (18F-FDG)
Normalized name: Fluorine (18F) fludeoxyglucose
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan
Study: NCT01806675
Drug: 18F-FPPRGD2
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.
Study: NCT00770601
Drug: Canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01770171
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg
Study: NCT01770171
Drug: Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
Study: NCT01423253
Drug: Lurasidone
Normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lurasidone 20, 40, or 60 mg/day, orally, once daily (QD) in the evening, with a meal or within 30 minutes after eating, flexibly dosed
Study: NCT03867617
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment during first month post-transplant.
Study: NCT00778622
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 500mg tid, 1500 mg/day, 16 weeks
Study: NCT00698464
Drug: Pasireotide
Normalized name: Pasireotide
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single subcutaneous injection of 600 µg of Pasireotide.
Study: NCT01498588
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive 4 cycles of neoadjuvant eribulin followed by 4 cycles of dose-dense doxorubicin and cyclophosphamide (AC).
Study: NCT01498588
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Growth factor support (pegfilgrastim) can be given at the discretion of the investigator. Administration of pegfilgrastim is required 24 to 48 hours following administration of dose-dense doxorubicin and cyclophosphamide.
Study: NCT03529929
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 day dosing as dictated by Medrol 6 Day Dose Pack
Study: NCT02186665
Drug: calcitriol ointment
Normalized name: Calcitriol Ointment
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02945813
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 850mg PO BID; 48 weeks
Study: NCT00270465
Drug: VRC-HIVDNA016-00-VP
Normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00270465
Drug: VRC-HIVADV014-00-VP
Normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02927587
Drug: The induction Cet of propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The induction Cet of propofol was targeted respectively at 1 and 2 ug/ml.
Study: NCT00716846
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg
Study: NCT00716846
Drug: pitavastatin
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2mg
Study: NCT01251120
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg intravenously every 4 weeks plus background DMARDs (including methotrexate)
Study: NCT00628134
Drug: calfactant
Normalized name: Calfactant
DrugBank: Calfactant (DB06415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single inhaled dose by nebulizer
Study: NCT00005818
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00005818
Drug: semaxanib
Normalized name: Semaxanib
DrugBank: Semaxanib (DB06436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01247194
Drug: PPI-461
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, oral, once daily for 3 days
Study: NCT01822522
Drug: Cabozantinib S-malate
Normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03302247
Drug: Nivolumab+Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine is added to the Nivolumab treatment
Study: NCT01898689
Drug: Ropivacaine 0.1%
Normalized name: ROPivacaine 0.1% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A sciatic catheter was inserted and ropivacaine 0.1% was administered as a basal infusion for 6 hours.
Study: NCT01898689
Drug: Ropivacaine 0.4%
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A sciatic catheter was inserted and ropivacaine 0.4% was administered as a basal infusion for 6 hours.
Study: NCT01807923
Drug: Lumacaftor Plus Ivacaftor Combination
Normalized name: ivacaftor / lumacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed dose combination tablet
Study: NCT01807923
Drug: Ivacaftor
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Film-coated tablet
Study: NCT06713785
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 1mg/ml Oral Solution
Study: NCT02371603
Drug: Pioglitazone 15 mg Tablet
Normalized name: pioglitazone 15 MG
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: White to off-white, round, convex, non scored tablet with ACTOS on one side, and 15 on the other, to be taken orally in the fasted state in the morning
Study: NCT00890929
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg, 10 mg, 25 mg, and/or 50 mg of lenalidomide administered PO from day 8 to Day 28 of each cycle
Study: NCT00890929
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75 mg/m2 Azacitidine administered intravenously (IV) or subcutaneously (SC) for days 1 to 7 of each cycle
Study: NCT02371603
Drug: Trimethoprim 100 mg Tablet
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: White, round, scored, convex tablet, debossed 93 above the score and debossed 2159 below the score on one side and plain on the other, to be taken orally as two tablets once in the morning and once in the evening
Study: NCT00409097
Drug: Rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00995007
Drug: ZD6474 (Vandetanib)
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vandetanib is an oral medication known to block angiogenesis and has shown significant antitumor activity in laboratory and animal studies. Vandetanib appears to be well tolerated by patients at specific daily doses.
Study: NCT00995007
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin is a drug that interrupts division of cancer cells and has been shown to be a useful drug in treatment of tumors known as gliomas. It is a useful drug for treating brain tumors, but researchers are interested in gathering more information about how it works as a treatment for patients who have not responded to initial surgery, radiation, or chemotherapy.
Study: NCT04659525
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
Study: NCT04659525
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
Study: NCT04551950
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin was administered intravenously as per standard of care.
Study: NCT04551950
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel was administered intravenously as per standard of care.
Study: NCT01491217
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HM30181AK 15 mg tablet + Paclitaxel 10mg, 30mg capsules
Study: NCT05208801
Drug: Percutaneous injection
Normalized name: TEA LEAF 0.1 g in 1 mL PERCUTANEOUS INJECTION, SOLUTION
DrugBank: Tea leaf (DB10580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sham procedure of 2 ml of 1% lidocaine injected percutaneously using the initial 25G needle for local anesthetics
Study: NCT05208801
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal injection of morphine 400mcg
Study: NCT04551950
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab was administrated as indicated for standard of care.
Study: NCT04551950
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin was administered intravenously as per standard of care.
Study: NCT02639520
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 sachet of 8 g of granules; one single dose on Day 1
Study: NCT05208801
Drug: Morphine+Bupivacaine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal injection of 5mg of 0.5% bupivacaine chloride
Study: NCT02639520
Drug: Fosfomycin trometamol-placebo
Normalized name: trometamol
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 sachet of 8 g of granules; one single dose on Day 1
Study: NCT03270332
Drug: Albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation of 270μg albuterol through a spacer
Study: NCT02073734
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 8mg/IV
Study: NCT02937558
Drug: Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide
Study: NCT02451943
Drug: Olaratumab
Normalized name: Olaratumab
DrugBank: Olaratumab (DB06043)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered IV
Study: NCT02112864
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg (2.5 ml)
Study: NCT04666454
Drug: Dipyridamole 200 mg
Normalized name: dipyridamole 200 MG
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg b.i.d
Study: NCT04666454
Drug: Apixaban 5 mg Oral Tablet
Normalized name: apixaban 5 MG Oral Tablet
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5mg b.i.d
Study: NCT02777489
Drug: Perindopril
Normalized name: Perindopril
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perindopril Bluepharma 8 mg tablets, daily, during approximately 12 weeks
Study: NCT04018157
Drug: Ketamine and dexmedetomidine and propofol and 0.9%saline
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive single intravenous bolus of combination from ketamine 0.5mg/kg and dexmedetomidine 1ug/kg in one syringe diluted in 10 ml 0.9% saline.
Study: NCT03770780
Drug: SAGE-718
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-718 in combination with Ketamine
Study: NCT04193878
Drug: Inhaled budesonide and formoterol
Normalized name: formoterol and budesonide
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: aerosolized doses of budesonide (1.0 mg/2 ml) and formoterol (20 mg/2 ml) twice daily for up to 5 days
Study: NCT04134676
Drug: Conditioned Media
Normalized name: Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media
DrugBank: Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media (DB15728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioned Media represents the complete regenerative milieu of cell-sourced secretome and vesicular elements. The soluble components of the secretome may be separated from the microvesicle fraction by centrifugation, filtration, polymer precipitation-based methodologies, ion exchange chromatography and size-exclusion chromatography. Both of these components may be capable of independently triggering regeneration and repair as well as of mediating the de novo organogenesis of tissue-engineered organs ex vivo.
Study: NCT01180296
Drug: oral micronized progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral micronized progesterone = 400 mg oral micronized progesterone nightly from 16 to 34 weeks
Study: NCT00210730
Drug: epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00035568
Drug: Glucovance (metformin HCl/glyburide)
Normalized name: glyburide / metformin hydrochloride Oral Tablet [Glucovance]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00035568
Drug: or Metformin HCl alone
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00035568
Drug: or Glyburide alone.
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00166439
Drug: Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rituximab 375 mg/m2 IV Weekly x 4 1 cycle only~dexamethasone 40 mg PO/IV Days 2-5 q 21 days 2 cycles~oxaliplatin 130 mg/m2 IV Day 2 q 21 days 2 cycles~cytosine arabinoside 2000 mg/m2 x 2 doses IV Days 2-3 q 21 days 2 cycles~pegfilgrastim 6 mg SQ Day 4 q21 days 2 cycles
Study: NCT03401385
Drug: Datopotamab Deruxtecan (Dato-DXd)
Normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total anti-TROP2 antibody and MAAA-1181a
Study: NCT03401385
Drug: Steroid Containing Mouthwash
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A mouthwash containing a steroid ingredient administered in sub-study
Study: NCT03482492
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol iv
Study: NCT03482492
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol iv
Study: NCT01327469
Drug: Albendazole, 2 x 400mg
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 2 x 400mg
Study: NCT01327469
Drug: Albendazole 400mg
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 400mg
Study: NCT01327469
Drug: Mebendazole 500mg
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole 500mg
Study: NCT01327469
Drug: Mebendazole 2 x 500mg
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole 2 x 500mg
Study: NCT01327469
Drug: Pyrantel-oxantel + mebendazole
Normalized name: oxantel
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrantel-oxantel + mebendazole
Study: NCT02048085
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For ticagrelor arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with ticagrelor 180 mg prior to PCI followed by maintenance dose of 90 mg bid.
Study: NCT02048085
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For clopdigrel arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with clopidogrel 300 mg prior to PCI followed by maintenance dose of 75 mg QD
Study: NCT00930228
Drug: Flutamide
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide, 250 mg capsule for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
Study: NCT00429572
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m\^2 intravenously Daily for 5 Days
Study: NCT00429572
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70 mg/m\^2 intravenously Daily for 2 Days
Study: NCT01375361
Drug: Albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg Albuterol inhaled on enrollment and at 4 hours in the emergency department.